Media center

We provide ongoing updates on our commercial, clinical and financial progress through regular press releases, presentations and webcasts, which can be accessed through the company’s media center.

Press Releases

Circassia Announces FDA Approval of Duaklir® for Maintenance Treatment of Chronic Obstructive Pulmonary Disease

Click here to download the full press release – Duaklir® launch planned H2 2019 – – Duaklir® to join Tudorza® in Circassia’s portfolio of US COPD products – Oxford, UK – 1 April 2019: Circassia...

Circassia Announces FDA Approval of Tudorza® Supplemental New Drug Application

This announcement contains inside information for purposes of Article 7 of Market Abuse Regulation 596/2014 Click here to download the full press release – Data showing reduction in COPD exacerbations and no increase in major...

Circassia Announces Successful Completion of FDA Pre-submission Meeting for Novel Nitric Oxide Product AirNOvent

Click here to download the full press release Oxford, UK – 4 February 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its partner,...

More press releases

In this section

Press releases

Presentations

Webcasts & audio

Image library

Media contacts